title: STAT inhibitors for cancer therapy.
abstract: Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development of these compounds.
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA. delong_liu@nymc.edu.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Furqan
authors.forename: Akintunde
authors.initials: A
authors.lastname: Akinleye
authors.forename: Nikhil
authors.initials: N
authors.lastname: Mukhi
authors.forename: Varun
authors.initials: V
authors.lastname: Mittal
authors.forename: Yamei
authors.initials: Y
authors.lastname: Chen
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009841:Oligonucleotides / Q000494:pharmacology; D057786:Peptidomimetics / Q000494:pharmacology; D050791:STAT Transcription Factors / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D009841:Oligonucleotides; D057786:Peptidomimetics; D050791:STAT Transcription Factors